Annexon (NASDAQ:ANNX) is a biopharmaceutical company focused on developing novel therapies for patients with autoimmune and neurodegenerative disorders. Their innovative approach targets the classical complement cascade, a crucial part of the immune system, aiming to halt or prevent the progression of these conditions. The company's portfolio includes several candidates in clinical trials, targeting diseases like Guillain-Barre Syndrome, amyotrophic lateral sclerosis (ALS), and Huntington's disease, among others. With a commitment to transforming the lives of patients through groundbreaking research, Annexon's objective is to pioneer treatments that can significantly improve outcomes for individuals facing these challenging diseases.